Many studies have concluded that inhibition of IKur could prolong the AP duration (APD) of atrial fibrillation patients [11,12], and by this, it can terminate the fibrillation, indicating that Kv1.5 is a potential target for atrial fibrillation therapy [13,14,15,16,17]. Here, KCNA5 is linked to atrial fibrillation.